🤔Why the numbers vary
Reported rates differ by source, by complication category (acute vs. long-term, major vs. minor), and by follow-up duration. Three windows are worth distinguishing:
Major complications — short-term
The most robust recent studies, often comparing transvenous devices to newer leadless ones, place the risk of a major complication — pneumothorax, cardiac perforation, or infection requiring device extraction — within the first year at approximately 2.7% to 4.0%.
Total complications — short to mid-term
Broader studies measuring any complication (lead dislodgement, pocket hematoma, pneumothorax) within 30 to 90 days report rates between 3.8% and 12.4%.
Long-term risks
Risk does not disappear after the implant heals. Across a patient's lifetime, lead-related and pocket-related complications accumulate:
- Infection: affects 1.2% to 2.2% of patients, often requiring complete system removal.
- Lead failure: mechanical stress on the leads over years results in failure of approximately 5.5% of leads after an average of 3.6 years.
- Tricuspid valve damage: the lead crossing the valve can cause significant regurgitation in 10% to 20% of patients.
📊Breakdown by complication type
To clarify what kind of complications occur, the following table summarizes specific risks reported in the literature:
| Complication type | Estimated rate | Timeline / notes |
|---|---|---|
| Any complication (overall) | 3.8% – 12.4% | Broad range including minor procedural issues. |
| Major complications | ~2.7% – 4.0% | Life-threatening or requiring significant intervention. |
| Pneumothorax | 0.2% – 2.9% | Collapsed lung due to vein access. |
| Infection | 1.2% – 2.2% | Risk persists for years post-implant. |
| Significant tricuspid regurgitation | 10% – 20% | Valve leak caused by the pacing lead. |
| Pacing-induced cardiomyopathy | ~10% | Heart failure due to chronic RV pacing pattern. |
| Venous occlusion | 20% – 60% | Clotting/blockage of arm or chest veins (often asymptomatic). |
📝Clinical context
Patient selection matters
Complication rates are strongly influenced by patient factors. A 2023 study analyzing a large U.S. inpatient database found that patients receiving leadless pacemakers — a newer technology — had a higher likelihood of in-hospital mortality and vascular complications compared to those receiving transvenous devices.
The authors noted this was likely driven by the fact that leadless recipients had significantly higher rates of comorbidities; in other words, sicker patients were being selected for the leadless approach, not that the technology itself was inferior. Direct, risk-adjusted comparisons remain essential when interpreting these data.
ABC Farma — Cardiac Electrophysiology Library
Bilingual, evidence-based clinical content on leadless pacemakers, LBBAP, PICM, and modern device therapy.
Visit www.abcfarma.net